1
Home
Companies

Entrada Therapeutics

#7107

Rank

$487.74M

Marketcap

US United States

Country

Entrada Therapeutics
Leadership team

Mr. Nathan J. Dowden (Chief Operating Officer)

Mr. Dipal Doshi (Pres, CEO & Director)

Dr. Natarajan Sethuraman Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Emergency Medicine, Genetics, Health Care, Medical
Number of Employees
100 - 500
Headquarters
Boston, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001689375
Traded as
TRDA
Social Media
URL
https://www.entradatx.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
History

Entrada was founded in Cambridge, Massachusetts, in 2014. In 2018, the company entered into a strategic collaboration with Genentech which accelerated its growth and enabled the company to build a stronger team, focus on advancing multiple clinical programs and develop its internal capabilities.

Mission
To bring safe and effective therapies to patients suffering from rare, monogenic diseases with limited or no approved treatment options.
Vision
To become a leader in the precision treatment of rare diseases and provide solutions to improve care delivery and patient quality of life.
Key Team

Mr. Kory James Wentworth CPA (CFO & Treasurer)

Dr. Jared Cohen J.D., Ph.D. (Gen. Counsel)

Ms. Karla MacDonald (Chief Corp. Affairs Officer)

Ms. Kerry Robert M.S. (VP of People)

Dr. Nerissa C. Kreher M.B.A., M.D., M.S. (Chief Medical Officer)

Recognition and Awards
Entrada has been recognized for its innovative approach to drug development having been named a 2020 FierceBiotech Fierce15 company, a 2019 FierceBiotech Fierce15 company, the 2019 MassBio Rising Star, the ESTEEM Top Emerging Innovator of 2019, the 2018 Venture Summit's Most Disruptive Biotechnology Company and the 2018 Fierce Pharma Innovation Summit Best in Show
References

https://in.investing.com/equities/entrada-therapeutics

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/entrada-therapeutics

https://finance.yahoo.com/quote/TRDA/

https://www.entradatx.com

https://sec.report/CIK/0001689375

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Entrada Therapeutics
Leadership team

Mr. Nathan J. Dowden (Chief Operating Officer)

Mr. Dipal Doshi (Pres, CEO & Director)

Dr. Natarajan Sethuraman Ph.D. (Chief Scientific Officer)

Products/ Services
Biotechnology, Emergency Medicine, Genetics, Health Care, Medical
Number of Employees
100 - 500
Headquarters
Boston, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001689375
Traded as
TRDA
Social Media
URL
https://www.entradatx.com